Linked Data API

Show Search Form

Search Results

1714079
human indexable true more like this
published true more like this
registered interest false more like this
answer date less than 2024-05-01more like thismore than 2024-05-01
date less than 2024-04-26more like thismore than 2024-04-26
date tabled less than 2024-04-26more like thismore than 2024-04-26
ddp created less than 2024-04-26T14:04:53.670Zmore like thismore than 2024-04-26T14:04:53.670Z
answering body
Department of Health and Social Care more like this
question status Tabled more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
ddp modified
less than 2024-04-26T14:17:33.536Zmore like thismore than 2024-04-26T14:17:33.536Z
less than 2024-05-01T09:34:04.197Zmore like thismore than 2024-05-01T09:34:04.197Z
hansard heading Gabapentin more like this
house id 1 more like this
identifier 23890 more like this
legislature
25259
parliament number 58 more like this
question first answered
less than 2024-05-01T09:02:05.22Zmore like thismore than 2024-05-01T09:02:05.22Z
question text To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin. remove filter
session
2023/24 more like this
session number 4 more like this
tabling member constituency York Central more like this
tabling member printed
Rachael Maskell more like this
title House of Commons Tabled Parliamentary Question 2023/24 23890 more like this
type
WrittenParliamentaryQuestion
uin 23890 more like this
version 1 more like this
written parliamentary question type NamedDay more like this
answer answer
creator
4471
label Biography information for Rachael Maskell more like this
publisher 25259
tabling member
4471
label Biography information for Rachael Maskell more like this